Astellas enters into strategic collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd.
Clients Xyphos Biosciences, Inc.
Jones Day represented Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., "Astellas") in connection with a research collaboration and exclusive option license agreement with ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company. Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary LENSai in silico generated antibodies, targeting an undisclosed target in the tumor microenvironment, as potential therapeutic development candidates. Targeting this molecule has the potential to markedly enhance anti-tumor immunity with other Astellas therapies including chimeric antigen receptor-based (CAR) technologies. Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.